Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Garcia-Esteve L, Torres A, Navarro P, Aguado J, Ascaso C. Maternidad the planned y psicomorbilidad: un riesgo evitable / Unplanned pregnancy and psychological morbidity: an avoidable risk. Fac Med Barc. 2005 Jul;32(3):111-8.